Breast Cancer

E.U. MR application completed for Arimidex

Published in Women's Health Weekly, December 19th, 2002

AstraZeneca announced that it has successfully completed the European application (under the Mutual Recognition Process) for the use of Arimidex as adjuvant treatment in postmenopausal women with early breast cancer.

The U.K. Medicines Control Agency (MCA) was the Reference Member State for the MR application with Austria, Germany, Italy, Portugal, and Spain as Concerned Member States.

With this news, Arimidex will become the first and only aromatase inhibitor available for use in the adjuvant treatment of early invasive breast cancer in postmenopausal women in these E.U. countries, giving physicians and patients a real choice for treatment. It is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-12-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry